Pelthos Therapeutics Inc. (PTHS)

↓ Download CSV

CIK 0001919246 · NYSE · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated NV
  • Fiscal year ends Dec 31

In fiscal 2025, Pelthos Therapeutics Inc. reported revenue of $16.80M. The company ran a net loss, with a net margin of -257.9%. It held $130.40M in total assets against $91.52M in total liabilities.

Key ratios (FY2025)

-193.1%
Operating margin
-257.9%
Net margin
-111.4%
Return on equity
Metric (FY)20252024202320222021
Revenue$16.80M$0
Cost of Revenue$3.99M$0
Operating Income-$32.43M-$7.57M-$6.86M-$2.32M
Net Income-$43.32M-$7.96M-$7.38M-$2.46M
EPS (Diluted)$-23.04$-14.27$-5.78$5.65
Total Assets$130.40M$1.37M$96.4K$55.1K
Total Liabilities$91.52M$4.08M$6.54M$3.76M
Shareholders' Equity$38.88M-$2.71M-$6.45M-$3.71M-$3.68M
Cash & Equivalents$17.97M$513.0K$100.0K$100.0K
Operating Cash Flow-$22.59M-$5.79M-$981.0K-$1.57M
Capital Expenditures$99.0K$0
Shares Outstanding3.23M610.4K3.91M1.11M